Clinical Trial Update: A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the safety and efficacy of durvalumab in combination with daratumumab for relapsed/refractory multiple myeloma; study terminated with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• Durvalumab (durvalumab)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2023-02-21